RecruitingPhase 1Phase 2NCT04199741

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

Immuno-PET Imaging of Neuroendocrine Tumors Using 89Zr-DFO-SC16.56, a DLL3-targeting Monoclonal Antibody

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

53 participants

Start Date

Dec 11, 2019

Study Type

INTERVENTIONAL

Conditions

Small Cell Lung Cancer Small Cell Lung Carcinoma

Summary

The purpose of this study is to look at how safe 89Zr-DFO-SC16.56 is, and how it is processed by the body in people with small cell lung cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using a special PET/CT scan with a new imaging agent (89Zr-DFO-SC16.56) to better detect and visualize small cell lung cancer and other related tumors in the body, helping doctors see where cancer is located more accurately. **You may be eligible if...** - You are 4 years of age or older - You have confirmed small cell lung cancer (new or recurrent), small cell carcinoma of unknown origin, or another type of neuroendocrine tumor - You have confirmed or suspected prostate cancer with neuroendocrine features - You have a suspected primary brain tumor or certain childhood cancers (Ewing's sarcoma, neuroblastoma, Wilms tumor, etc.) - You have at least one measurable tumor on CT, MRI, or other imaging **You may NOT be eligible if...** - You do not have a detectable tumor lesion on imaging - You are unable to consent or comply with the imaging procedures Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.